CD19/22 CAR-T cells therapy (Minsk Scientific-Practical Center For Surgery)

N/A

Report date: 2025/09/10 20:01:13

Base Information

Drug NameCD19/22 CAR-T cells therapy (Minsk Scientific-Practical Center For Surgery)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsCD22 modulators

TargetsB-lymphocyte antigen CD19CD22

Therapy Area/IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelarus

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesMinsk Scientific-Practical Center For Surgery, Transplantation And Hematology

China Registration ClassN/A

Develop Information

Active CompaniesMinsk Scientific-Practical Center For Surgery, Transplantation And Hematology

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A